Risperidone market is experiencing significant advancement, driven by regulatory approvals, expanded therapeutic indications, and increasing innovation in long-acting injectable (LAI) drug delivery systems. These developments are particularly important in the treatment of chronic psychiatric disorders such as schizophrenia and bipolar I disorder, where long-term adherence to medication remains a major clinical challenge. Recent updates from Teva Pharmaceutical Industries Ltd., Medincell, Amneal Pharmaceuticals, Inc., and Lupin Limited highlight strong momentum across regulatory, clinical, and technological fronts.
A key breakthrough occurred in October 2025 when Teva Pharmaceutical Industries Ltd., in partnership with Medincell, received U.S. FDA approval for UZEDY® (risperidone extended-release injectable suspension) for the maintenance treatment of bipolar I disorder (BD-I) in adults. This approval significantly expands the product’s earlier indication for schizophrenia, positioning it as a versatile long-acting therapy. UZEDY is the first subcutaneous LAI formulation of risperidone and utilizes Medincell’s proprietary SteadyTeq™ copolymer technology to enable controlled and sustained drug release. The therapy offers flexible dosing intervals, allowing administration once monthly or once every two months, with therapeutic plasma concentrations achieved within 6 to 24 hours after injection. The approval was supported by extensive prior clinical data, including findings from Phase 3 studies such as the RISE and SHINE trials, along with Model-Informed Drug Development (MIDD) approaches that leveraged existing evidence on risperidone’s safety and efficacy.
Earlier in February 2025, Teva and Medincell had announced that the FDA accepted the supplemental New Drug Application (sNDA) for UZEDY for the bipolar I disorder indication. This marked a critical regulatory milestone that ultimately led to the October 2025 approval. The expanded indication is particularly significant given that bipolar I disorder affects approximately 1% of the U.S. population—over 3.4 million adults—and is associated with high relapse rates, poor long-term outcomes, and increased mortality. Long-acting injectables such as UZEDY are increasingly recognized for their ability to improve adherence and reduce relapse risk compared to daily oral therapies.
Further strengthening the risperidone landscape, Amneal Pharmaceuticals, Inc. received FDA approval in September 2025 for risperidone extended-release injectable suspension in multiple strengths (12.5 mg, 25 mg, 37.5 mg, and 50 mg per vial). This product references Risperdal Consta® and qualifies for 180-day exclusivity under the FDA’s Competitive Generic Therapy (CGT) designation. The approval reflects Amneal’s leadership in developing complex injectables, particularly those involving advanced microsphere formulations and cold-chain manufacturing processes. With estimated U.S. annual sales of approximately $194 million for the reference product, this approval is expected to enhance market competition while expanding patient access to long-acting psychiatric treatments. The company has indicated plans to launch the product in the fourth quarter of 2025.
Similarly, Lupin Limited achieved a major milestone in September 2025 with FDA approval of its risperidone extended-release injectable suspension (25 mg, 37.5 mg, and 50 mg single-dose vials). This product, also granted 180-day CGT exclusivity, represents the first commercial output from Lupin’s subsidiary Nanomi’s long-acting injectable platform. Nanomi’s proprietary particle-control technology enables the production of highly uniform microspheres, ensuring consistent drug release profiles over extended durations, improved injectability through smaller needles, and enhanced therapeutic outcomes. The product is bioequivalent to Risperdal Consta® and is indicated for the treatment of schizophrenia as well as for the maintenance treatment of bipolar I disorder, either as monotherapy or adjunctive therapy with lithium or valproate. This development underscores Lupin’s strategic focus on complex generics and specialty drug delivery systems.
In addition to regulatory progress, 2026 individual participant data meta-analysis reported multiple adverse outcomes associated with risperidone use in individuals with dementia. These findings reinforce existing boxed warnings regarding increased mortality risk in elderly patients with dementia-related psychosis and highlight the importance of cautious prescribing and patient monitoring. While risperidone remains a cornerstone therapy in psychiatric care, such research emphasizes the ongoing need to balance efficacy with safety, particularly in vulnerable populations.
Overall, the risperidone market is evolving rapidly, supported by expanded FDA approvals, technological innovation in long-acting formulations, and a growing emphasis on improving adherence and long-term outcomes. Companies including Teva, Medincell, Amneal, and Lupin are playing a central role in shaping the future of psychiatric treatment through advanced injectable therapies that address unmet clinical needs.
